Stocks to Sell: Vertex Pharmaceuticals (VRTX)
Last but not least, owners of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) may want to lock in their sizable gains while they can.
It’s the number-one winner in the S&P 500 so far this year, boasting a well-deserved 60% since the end of 2016 largely thanks to a 20% jump it made on March 29. That’s when the company announced its cystic fibrosis drug Kalydeco performed very well in late-stage testing. Just for the record though, VRTX was rallying before the big move and has continued its climb after the fact.
There’s only so much mileage a company can get from one event, however, and all the potential upside of Kalydeco is already priced into the stock. In fact, with the huge gap from March 29 still unfilled, VRTX is apt to be one of the first names traders pull the plug on should the market-wide situation worsen.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.